Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching-Reference-Cited by-同舟云学术

Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching

Published:2022-08-15 Issue:8 Volume:14 Page:1510-1527
ISSN:1948-5204
Container-title:World Journal of Gastrointestinal Oncology
language:
Short-container-title:WJGO

Author:

Adhoute Xavier,De Matharel Marie,Mineur Laurent,Pénaranda Guillaume,Ouizeman Dann,Toullec Clemence,Tran Albert,Castellani Paul,Rollet Armelle,Oules Valérie,Perrier Hervé,Si Ahmed Si Nafa,Bourliere Marc,Anty Rodolphe

Publisher

Baishideng Publishing Group Inc.

Subject

Gastroenterology,Oncology

Reference50 articles.

1. Sorafenib in Advanced Hepatocellular Carcinoma

2. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma

3. Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

4. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

5. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes and safety of atezolizumab plus bevacizumab in the treatment of hepatocellular carcinoma: treatment prognosis and comparison with tyrosine kinase inhibitors in a French multicenter matched real-life study;European Journal of Gastroenterology & Hepatology;2024-07-26

2. Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives;Discover Oncology;2024-07-03

3. Systemic Treatment in Intermediate Stage (Barcelona Clinic Liver Cancer-B) Hepatocellular Carcinoma;Cancers;2023-12-21

4. Impact of post‐progression survival in second‐line treatment with molecular target agents for unresectable hepatocellular carcinoma;Hepatology Research;2023-11-04

5. Characteristics of cabozantinib treatment in advanced hepatocellular carcinoma;Liver Cancer International;2023-09